ClinicalTrials.gg
CompletedNCT05028764Updated Feb 24, 2022

Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers

An observational study in Friedreich Ataxia and Healthy Volunteers, sponsored by Larimar Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by Larimar Therapeutics, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
12th of 21
60 · median 65
Started
2021
with 4 others
Observational
21 of 71
8 open now
Registered
43rd of 71
by date
Lead sponsor
8 of 71
Larimar Therapeutics, Inc.

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 12th largest by enrollment of the 21 observational ones that give a count, is one of 5 that started in 2021, is one of 21 observational ones, and was the 43rd registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without Friedreich's ataxia (FRDA).

Read the detailed description

Primary Objective: To examine the range of tissue frataxin (FXN) concentrations in the buccal cells, blood, and skin cells of normal healthy volunteers without FRDA.

Secondary Objective: To examine the range of specific ribonucleic acids (RNAs), other proteins, and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without FRDA.

03

Conditions studied

  • Friedreich Ataxia
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects will be recruited from the community.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a healthy male or female,18-50 years of age
  2. Subject has a (BMI) ≥18.0 and ≤32.0 as of the screening visit.
  3. Subject is racially Caucasian, Asian, Native Hawaiian, or Native American.

Exclusion criteria

Exclusion Criteria:

  1. Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to the Day 1 (assessment) visit.
  2. Subject has a chronic condition that requires ongoing prescription drug treatment.
  3. Subject use of any statin medications within 3 months before the Day 1 (assessment) visit.
  4. Subject use of any lipid-lowering agents, other than statins, within 6 weeks before the Day 1 (assessments) visit.
  5. Subject is racially black or African American.
  6. Pregnant or breast-feeding female subjects.
  7. Subject has a known history of drug or alcohol abuse or current suspected drug or alcohol abuse.
  8. Subject is positive for (HIV), virus (HCV), surface antigen (HBsAg), or hepatitis A virus (HAV).
  9. Subject has any condition, disease, or situation, that in the opinion of the principal investigator (PI), could confound the results of the study or put the subject at undue risk, making participation inadvisable.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • 18 to 30 years of age group

    Consisting of at least 13 males and 13 females

    Diagnostic Test: Buccal Swabs, Blood Draws and Skin Punch Biopsy

  • 31 to 50 years of age group

    Consisting of at least 13 males and 13 females

    Diagnostic Test: Buccal Swabs, Blood Draws and Skin Punch Biopsy

Interventions

  • Diagnostic testBuccal Swabs, Blood Draws and Skin Punch Biopsy

    Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers

06

What researchers measure

Primary outcomes

  1. Examine tissue frataxin concentrations in buccal cells, blood and skin cells

    Range of tissue frataxin levels in buccal cells, blood and skin cells

    Time frame: 1 day

Secondary outcomes

  1. Examine specific ribonucleic acids (RNAs), other proteins, and specialized lipids in buccal cells and blood

    Range of specific ribonucleic acids (RNAs), other proteins, and specialized lipids in buccal cells and blood

    Time frame: 1 day

07

Study locations

1 site
  • Clinilabs Drug Development Corporation
    Eatontown, New Jersey 07724, United States
08

References and documents

Publications

  • Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, Lynch DR. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010 Oct-Nov;101(2-3):238-45. doi: 10.1016/j.ymgme.2010.07.001. Epub 2010 Jul 8. PubMed 20675166 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Feb 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 31, 2021
StartActual
Aug 4, 2021
Primary completionActual
Feb 4, 2022
CompletionActual
Feb 4, 2022
Last update
Feb 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05028764
Lead sponsor
Larimar Therapeutics, Inc.
Collaborators
Clinilabs, Inc.
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Aug 4, 2021
Primary completion
Feb 4, 2022
Completion
Feb 4, 2022
Last update
Feb 24, 2022

Study contacts

Magdy Shenouda, M.D.
principal investigator · Clinilabs, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion